Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review

JAMA

Volumn 286, Issue 18, 2001, Pages 2270-2279

  Phillips, Kathryn A ^a   Veenstra, David L ^b   Oren, Eyal ^a   Lee, Jane K ^a   Sadee, Wolfgang ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CARDIOVASCULAR AGENT; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DIGOXIN; DIURETIC AGENT; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; FLUOXETINE; INSULIN; ISONIAZID; LISINOPRIL; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; POTASSIUM; PREDNISONE; RIFAMPICIN; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; WARFARIN;

ADVERSE DRUG REACTION; ALLELE; DATA BASE; EVALUATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; PUBLICATION; REVIEW; TREATMENT PLANNING;

EID: 0035861049     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.18.2270     Document Type: Review

References (91)

1. Safe health care: Are we up to it
2. Error in medicine: What have we learned
3. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies
4. Shattuck lecture: Medical and societal consequences of the human genome project
5. Implications of the Human Genome Project for Medical Science
6. Pharmacogenetics
7. Pharmacogenetics and future drug development and delivery
8. Pharmacogenomics: Teaching old drugs new tricks
9. Pharmacogenomics: Translating functional genomics into rational therapeutics
10. Pharmacogenetics and adverse drug reactions
11. Pharmacogenomics: The genomics of drug response
12. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: Relevance to xenobiotic metabolism and toxicity
13. Polymorphic cytochromes P450 and drugs used in psychiatry
14. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia
15. A functional polymorphism of the cytochrome P4501A2 (CYP1A2) gene: Association with tardive dyskinesia in schizophrenia
16. Adverse drug reactions in hospitalized patients: A critique of a meta-analysis
17. Drug-related-injury visits to hospital emergency departments
18. Visits to office-based physicians in the United States for medication-related morbidity
19. Incidence of adverse drug events and potential adverse drug events: Implications for prevention
20. Adverse drug reactions in hospital patients
21. Adverse drug events in hospitalized patients: Excess length of stay, extra costs, and attributable mortality
22. Probable adverse drug reactions in a rural geriatric nursing home population: A four-year study
23. Adverse drug events in hospitalized elderly
24. Adverse drug events in elderly patients receiving home health services following hospital discharge
25. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population
26. Adverse drug events in high risk older outpatients
27. Comparison of adverse drug reactions detected by pharmacy and medical records departments
28. Drug-related hospital admissions
29. Medication misadventures resulting in emergency department visits at HMO medical centers
30. Characteristics associated with ability to prevent adverse drug reactions in hospitalized patients
31. Drug related problems in emergency department patients
32. Medication related visits to the emergency department: A prospective study
33. Incidence and types of adverse events and negligent care in Utah and Colorado
34. Adverse drug reactions in a state psychiatric hospital
35. Pharmacogenetics of antidepressants: Clinical aspects
36. Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation
37. Pharmacogenetics of cytochromes P450
38. The Gerhard Zbinden Memorial Lecture. Genetic polymorphism of drug metabolizing enzymes: Implications for toxicity of drugs and other xenobiotics
39. Functional consequences of polymorphism of xenobiotic metabolising enzymes
40. Inherited variations in drug-metabolizing enzymes: Significance in clinical oncology
41. Laying the foundations for personalized medicines
42. Genetic polymorphism of drug metabolising enzymes in African populations: Implications for the use of neuroleptics and antidepressants
43. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia
44. Molecular mechanisms of genetic polymorphisms of drug metabolism
45. Genetic polymorphisms in human drug metabolic enzymes
46. Pharmacogenetics of sulfotransferase
47. Genetic epidemiology of environmental toxicity and cancer susceptibility: Human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues
48. Molecular genetics of the human cytochrome P450 monooxygenase superfamily
49. Update: Genetic polymorphism of drug metabolizing enzymes in humans
50. Cytochrome P450 enzyme system: Genetic polymorphisms and impact on clinical pharmacology
51. Individualization of cancer therapy based on cytochrome P450 polymorphism: A pharmacogenetic approach
52. Interpatient variability: Genetic predisposition and other genetic factors
53. Genetic polymorphism of drug metabolizing enzymes: New mutations in CYP2D6 and CYP2A6 genes
54. Human cytochrome P450 (CYP) genes: Recommendations for the nomenclature of alleles
55. Top 200 brand-name drugs by retail sales in 2000
56. Drug interactions
57. CYP3A4 activity in African American and European American men: Population differences and functional effect of the CYP3A4*aB 5′-promoter region polymorphism
58. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
59. Pharmacogenetics
60. Implications of the genetics revolution for health services research: Pharmacogenomics and improvements in drug therapy
61. Will genetics revolutionize medicine?
62. Pharmacogenomics
63. Pharmacogenetics as a molecular basis for individualized drug therapy: The thiopurine S-methyltransferase
64. Should HER2 status be routinely measured for all breast cancer patients?
65. HIV-1 drug resistance genotyping: A review of clinical and economic issues
66. Genomics and drugs: Finding the optimal drug for the right patient
67. Inventing the pharmacogenomics business
68. The human genome and medical care in the new century
69. The interface of genetics and public health: Research and educational challenges
70. Public health genetics: An emerging interdisciplinary field for the post-genomic era
71. Genetics and public health in the 21st century
72. Use of genotypic resistance testing to guide HIV therapy: Clinical impact and cost-effectiveness
73. Factors influencing health insurers' decisions to cover new genetic technologies
74. Pharmacogenomics: Today, tomorrow, and beyond
75. Computerized surveillance of adverse drug events in hospital patients
76. Incidence of adverse drug reactions in adult medical inpatients
77. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
78. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment